The ophthalmic drugs contract manufacturing market is estimated to be worth USD 1.7 billion in 2030, predicts Roots Analysis

 

Outsourcing has become a popular trend among ophthalmic drug developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages




Roots Analysis is pleased to announce the publication of its recent study, titled, “Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030.”

 

The report features an extensive study of the contract services market for ophthalmic products and solutions. It features in-depth analyses, highlighting the capabilities of a diverse set of CMOs and CDMOs. Amongst other elements, the report includes:

§  A detailed review of the ophthalmic drugs contract manufacturing market landscape, featuring a list of over 240 CMOs and analysis based on a number of relevant parameters.

§  A competitiveness analysis of prominent contract manufacturers, featuring insightful pictorial summaries and representations.

§  Elaborate profiles of key players that offer a diverse range of capabilities for the contract development, manufacturing and packaging of ophthalmic drug products.

§  A detailed clinical trial analysis of completed, ongoing and planned studies of various ophthalmic drug products.

§  An estimate of the overall, annual capacity for manufacturing ophthalmic APIs and drug FDFs based on data reported by industry stakeholders in the public domain.

§  An informed estimate of the annual clinical and commercial demand for ophthalmic APIs and drug FDFs.

§  A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, including a Harvey ball analysis highlighting the relative effect of each SWOT parameter on the overall industry.

§  A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing contract manufacturing services to ophthalmic drug developers.

§  A discussion on the emerging trends and potential market drivers, which are likely to impact the evolution of the market in the coming years.

§  A detailed list of over 55 ophthalmic medical device contract manufacturers, along with information on a number of relevant parameters.

 

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

§  Type of product

§  Ophthalmic API

§  Ophthalmic drug FDF

 

§  Type of FDF manufactured

§  Solid

§  Semi-solid

§  Liquid / suspension

 

§  Type of primary packaging

§  Ampoule / vial 

§  Glass / plastic bottle

§  Ointment tube

§  Blister packing

§  Other forms

 

§  Scale of manufacturing

§  Clinical

§  Commercial

 

§  Company size

§  Small

§  Mid-sized

§  Large

§  Very large

 

§  Target disease indication

§  Age-related macular degeneration

§  Dry eye

§  Glaucoma

§  Other disease segments

 

§  Key geographical regions

§  North America (US, Canada and Mexico)

§  Europe (UK, Germany, France, Spain, Italy and rest of Europe)

§  Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific)

§  Rest of the world

 

Key companies covered in the report

§  Akorn

§  Akums

§  Bal Pharma

§  Catalent

§  Cayman Chemical

§  Entod Pharmaceuticals

§  Farmigea

§  Glenmark Pharmaceuticals

§  Indiana Ophthalmics

§  Lomapharm

§  Medichem

§  Pillar5 Pharma

§  Recipharm

§  Salvat

§  Sterling Pharmaceutical Services

§  Sunways India

 

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html

 

Other Recent Offerings

1.   China Biopharmaceutical Contract Manufacturing Market, 2020-2030

2.   Pharmaceutical Continuous Manufacturing Market, 2020-2030

3.   Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030

 

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Medium - https://medium.com/@RootsAnalysis

Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/

Quora - https://rootsanalysisinsights.quora.com/

Location: United States

Comments

Post a Comment

Popular posts from this blog

The on-body drug delivery-related intellectual landscape report identifies and analyzes all relevant IP publications, featuring the contributions of both established and emerging technology developers

Image
Several innovative drug delivery technologies have gathered notable momentum (in terms of adoption and sales) soon after entering the market; most of these are designed to address the unmet needs of administering complex pharmacological interventions Roots Analysis has announced the addition of the “ On-body Drug Delivery Devices - Intellectual Property Landscape: Focus on Popular / Relevant Prior Art Search Expressions, Patent Valuation, Pockets of Innovation / White Spaces, and Key Applicant Profiles ” report to its list of offerings.   Since the early 20th century, over 12,000 patents / patent applications have been granted / filed in relation to drug delivery devices that can either be worn on the body ( or implanted ), by both industry and non-industry players. Presently, innovation in this domain is focused on developing cheaper and more environment friendly drug delivery systems, with provisions to minimize / altogether eliminate the risk of needlestick injuries. ...
Read more

Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030

Image
To order this detailed 350+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html   Key Inclusions §   A detailed assessment of the current market landscape, including information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target immune checkpoints, their respective mechanisms of action (inhibitory or stimulatory),  type of therapeutic modality used (monoclonal antibody, antibody fragment, small molecule and others), route of administration (intravenous, subcutaneous, oral and others), target disease indication, target therapeutic area and type of therapy (monotherapy, combination therapy and both).  §   A detailed analysis of more than 590 completed, ongoing and planned clinical studies of next generation immune checkpoint inhibitors and stimulators, highlighting prevalent trends across various relevant paramete...
Read more

The CAR-T cell therapy market is estimated to be worth USD 14 billion in 2030, predicts Roots Analysis

Image
  Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies are expected to achieve blockbuster status   Roots Analysis is pleased to announce the publication of its recent study, titled, “ CAR-T Cell Therapies Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2021-2030 ”   The features an extensive study of the current market landscape and the future potential of CAR-T cell therapies. The report highlights the efforts of both industry players and acade...
Read more